





Drugs used in tuberculosis

Objectives:

- Discuss the etiology of tuberculosis.
- Discuss the common route for transmission of the disease.
- Discusses the out line for treatment of tuberculosis.
- Discuss the drugs used in the first & second line Regarding:

-The mechanism of action

- -Adverse effects
- -Drug interactions
- -Contraindication
- Discuss tuberculosis & pregnancy.
- Discuss tuberculosis & breast feeding.



Titles
 Very important
 Extra information
 Doctor's notes

Tuberculosis

Etiology: Mycobacterium tuberculosis, slow growing, an acid fast bacillus.

Robert Koch was the first to see *Mycobacterium tuberculosis* with his staining technique in 1882.

Each year, 1% of the global population is infected.

More than one third of the world's population has tuberculosis.



Crowded, poorly ventilated houses promote growth of bacteria and chance of spreading infection. Isolation of patients is important. Individuals should not spit and should cover their mouth when coughing or sneezing.

Common sites of infections

- Apical areas of lung. oxygen rich areas
- Renal parenchyma.
- Growing ends of bones.

Treatment Of Tuberculosis

<u>Preventing development of drug</u> <u>resistance</u> is the most important reason to use drug combination.

Periods of treatment: (minimum 6 months).

Tuberculosis



Never use a single drug therapy!

- Isoniazid –rifampin combination administered for 9 months will cure 95-98% of cases.
- Addition of pyrazinamide/ethambutol for this combination for the first 2 months allows total duration to be reduced to 6 months.

Use four drugs for two months then use only INH/RIF to avoid toxicity as possible this will give you 6 months of treatment instead of 9 months using INH/RIF only

1st Line Treatment

	Isoniazid	Rifampin	Et	hambutol	Pyrazinamide	Streptomycin
About Drug	Bacteriostatic for resting bacilli. Bactericidal for rapidly growing bacilli.	Bactericidal	ctericidal Bacte		riostatic	Bactericidal
Mechanism of Action	Inhibits the synthesis of mycobacterial cell wall (inhibit the synthesis of mycolic acid)	Inhibits RNA m synthesis by binding ti to DNA a dependent RNA bar polymerase the enzyme. m		Inhibitor of ycobacterial arabinosyl ransferase (lters the cell rrier) disrupts e assembly of ycobacterial cell wall.	Unknown	Inhibitors of protein synthesis by binding to 30 S ribosomal subunits. Irreversible action.
Active Against	Intracellul	lar & extracellular bacilli			Intracellular Bacilli	Extracellular bacilli Highly polar, Given IV.
Clinical Use	-Treatment of TB - Latent TB in patients with positive tuberculin skin test -Prophylaxis against active TB in individuals who are in great risk	-Treatment of TB -Prophylaxis		-Treatment of TB in combinatio n with other drugs.	-Mycobacterial infections mainly in multidrug resistance cases. - Important in short –course (6 months) regimen. -Prophylaxis of TB.	-Severe, life-threating form of T.B. as meningitis, disseminated disease.
Drug Interactions	Enzyme inhibitor Slow and fast acetylators.	Enzyme inducer Clinically significant drug interactions such as warfarin, methadone will be metabolized faster			-	
ADR	 -Peripheral neuritis (pin & needles sensation in the feet) -Optic neuritis &atrophy.(Pyridoxine should be given in both cases) -Hepatitis (toxic metabolites) Hepatitis with INH, is age dependent; it is rare in persons younger than 20 years , risk increases with age and alcohol 	-Harmless red- orange discoloration of body secretions (saliva, sweat, tears). Tell the patient about this effect. Can permanently stain contact lenses. -Hepatitis less common compared to INH -Flu-like syndrome -Hemolytic		-Impaired visual acuity -red-green color blindness. contraindec ated in children under 5 years.	-Hepatotoxicity (common) - Hyperuricemia (gouty arthritis) -Drug fever & skin rash	-Ototoxicity -Nephrotoxicity -Neuromuscular block very dangerous that in high doses patient might die

2nd Line Treatment

	Ethionamide	Fluoroquinolones (Ciprofloxacin)	Rifabutin	Aminosalicylic Acid (PAS)
Mechanism of action	Inhibits the synthesis of mycolic acid	-	 - RNA inhibitor -Cross –resistance¹ with rifampin is complete. -Enzyme inducer (less potent than rifampin) 	Bacteriostatic inhibits Folic acid synthesis.
Active against			Extracellular and intracellular bacilli.	
Clinical use	As a secondary line agent ,treatment of TB.	Effective against multidrug- resistant tuberculosis	prevention and treatment of TB & <u>atypical TB²</u>	As a second line agent is used in the treatment of pulmonary & other forms of tuberculosis.
ADRs	 Teratogenic (interfering with the development of a fetus) Poorly tolerated due to : Severe gastric irritation & Neurological manifestations. 	-	- GIT intolerance - Orange-red discoloration of body secretions.	 GIT upset (shouldn't be used on empty stomach) -Crystalluria ³

 (1) Cross-resistance is the tolerance to a usually toxic substance as a result of exposure to a similarly acting substance.
 (2) Atypical TB: diseases caused by non-tuberculosis mycobacteria (NTM). E.g. M. leprae causes leprosy.
 (3) Crystalluria: the excretion of crystals in the urine, causing irritation of the kidney.

Indications:

- In the second second
- Resistance to 1st line drugs.
- Contraindication to 1st line drugs.
- Failure of clinical response .
- Used in typical & atypical tuberculosis.

TB & Pregnancy

- Untreated TB represents a great risk to the pregnant woman & her fetus than the treatment itself.

- First line (INH, Ethambutol and rifampicin) drugs are given for 9 months in normal doses.

- Streptomycin not used.

TB & Breast Feeding

- It is not a contraindication to receive drugs , but caution is recommended.

SAQ1

A 34-year-old foreign-born farm worker present to your clinic complaining of dark-red urine over the past several weeks. On further history, you learn that he had a positive PPD 2 months ago. At the time, a chest X-ray indicated a lesion in the right upper lobe, consistent with tuberculosis. He was started a multidrug therapy to eradicate the infection, which he states he is currently taking. The patient's physical examination is completely within normal limits. You reassure the patient that the urine discoloration is a harmless side effect of his medication, and you order a serum and urine studies to ensure that there is no indication of damage to liver or kidney.

Q1: Which anti-mycobacterial agent is the patient currently taking?

Q2: What is the mechanism of action of this drug?

Inhibits RNA synthesis by binding to DNA dependent RNA polymerase enzyme.

Q3: Describe the Drug-Drug interaction mechanism of this drugs.

This drug is an enzyme inhibitor which then will prolong the duration of action of any drug that is metabolized by enzymes as warfarin.

Q4: What other side effect could we see in this patient.

This drug causes discoloration of most of the body secretions including:

- Sweating.
- Tears.
- Urine.
- And saliva.

This drug also could cause nephritis and hepatitis. Hemolytic anemia. Flu like syndrome.



SAQ2

A 14-year-old foreign-born Hispanic women arrives at your pediatric clinic for an annual physical examination. She immigrated to the kingdom 2 years ago and she lives with her parents, younger brother, and maternal grandmother. Of note, the grandmother was just hospitalized 2 days ago for fever, chills, and cough with sputum that demonstrates acid-fast bacilli bacteria. The patient's parents note that the patient's PPD has been positive in the past due to BCG vaccination as an infant. She report no concerning symptoms and her physical examination is unremarkable. Nevertheless, given the grandmother's history, you decided to place the child on a prophylactic pharmacologic regimen to prevent active TB and you suggest that her brother and parents also consider prophylactic medication as well.

Q1: What is the drug of choice in this prophylactic therapy?

Q2: What is the mechanism of action of this drug.

It has bactericidal and bacteriostatic effects which is caused by Inhibition of the synthesis of mycobacterial cell wall (mycolic acid)

Q3: List the major side effect of this drug.

- Peripheral neuropathy due to vitamin B6 deficiency.
- Hepatitis.
- G6PD- deficient hemolytic anemia.

Q4: Describe the Drug-Drug interaction mechanism of this drugs.

This drug is an enzyme inhibitor which then will decrease the duration of action of the drugs that is metabolized by the enzymes such as warfarin.





QUIZ					
Boys	Girls				
عبدالرحمن ذكري	غادة المهنا				
عبدالعزيز رضوان	اللولو الصليهم				
مؤيد أحمد	روان القحطاني				
فيصل العباد	امل القرني				
فارس النفيسة	شروق الصومالي				
خالد العيسى	سما الحربي				
عبدالرحمن العريفي	انوار العجمي				
عبدالرحمن الجريان	وتين الحمود				
محمد خوجة	رنا باراسين				
عمر التركستاني					
us :					

Contact us :



@Pharma436

o Pharma436@outlook.com